Marinus Pharmaceuticals, Inc. is developing treatments for seizure disorders. ZTALMY® (ganaxolone) oral suspension, CV is approved for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients 2 years of age and older. Ganaxolone is being studied in other seizure disorders, including an IV formulation for refractory status epilepticus.